Literature DB >> 9673555

Ultrasound-guided laparoscopic cryoablation of hepatic tumors: preliminary report.

E Lezoche1, A M Paganini, F Feliciotti, M Guerrieri, F Lugnani, A Tamburini.   

Abstract

The purpose of this ongoing prospective study is to evaluate the feasibility, safety, and efficacy of a total laparoscopic approach for ultrasound-guided cryoablation of primary and secondary hepatic tumors. Of 56 patients who underwent ultrasound-guided cryoablation, a total laparoscopic approach was employed in 18 (5 men, 13 women; mean age 48.6 years, range 35-77 years). Fifteen patients were included for secondary hepatic tumors and three for primary hepatic tumors. Selection criteria were the presence of three or fewer nodules, less than 40% liver volume replaced by tumor, and absence of extrahepatic disease. Altogether 28 lesions were confirmed by intraoperative laparoscopic ultrasonography and were treated; 25 by ultrasound-guided laparoscopic cryoablation and 3 by laparoscopic wedge resection. After cryoablation, surface parenchymal splits with bleeding from the frozen tissue were observed in six patients and required conversion to open surgery in two patients whose lesions were located in segment 8. No major complication and no mortality were observed. One or more minor complications occurred in nine patients; they included pleural effusion (n = 8, 44.4%), subdiaphragmatic fluid collection ( n = 3, 16.6%), worsening hepatic insufficiency in a cirrhotic patient (n = 1, 5.5%), and wound infection in a patient converted to open surgery (n = 1, 5.5%). The mean hospital stay was 6.4 days (range 3-14 days). At a mean follow-up of 10.8 months (range 5-16 months) all patients are alive and 14 are disease-free, as demonstrated by normalization of tumor markers and negative magnetic resonance imaging. In carefully selected patients total laparoscopic ultrasound-guided cryoablation is feasible and safe. A longer period of follow-up is required to evaluate the efficacy of the procedure and its impact on survival.

Entities:  

Mesh:

Year:  1998        PMID: 9673555     DOI: 10.1007/s002689900478

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  7 in total

1.  Ultrasound-guided radiofrequency thermal ablation of liver tumors: percutaneous, laparoscopic, and open surgical approaches.

Authors:  J Machi; S Uchida; K Sumida; W M Limm; S A Hundahl; A J Oishi; N L Furumoto; R H Oishi
Journal:  J Gastrointest Surg       Date:  2001 Sep-Oct       Impact factor: 3.452

2.  Laparoscopy with laparoscopic ultrasound for pretreatment staging of hepatocellular carcinoma: a prospective study.

Authors:  M Montorsi; R Santambrogio; P Bianchi; E Opocher; G P Cornalba; G Dapri; L Bonavina; M Zuin; M Podda
Journal:  J Gastrointest Surg       Date:  2001 May-Jun       Impact factor: 3.452

Review 3.  Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases.

Authors:  Jan H M B Stoot; Robert J S Coelen; Mechteld C De Jong; Cornelis H C Dejong
Journal:  HPB (Oxford)       Date:  2010-10       Impact factor: 3.647

Review 4.  Locoregional therapies for hepatocellular carcinoma: a critical review from the surgeon's perspective.

Authors:  Ronnie Tung-Ping Poon; Sheung-Tat Fan; Flora Hau-Fung Tsang; John Wong
Journal:  Ann Surg       Date:  2002-04       Impact factor: 12.969

5.  Radiofrequency interstitial thermal ablation of hepatocellular carcinoma in liver cirrhosis. Role of the laparoscopic approach.

Authors:  M Montorsi; R Santambrogio; P Bianchi; E Opocher; M Zuin; E Bertolini; S Bruno; M Podda
Journal:  Surg Endosc       Date:  2001-02       Impact factor: 4.584

6.  Safety and efficacy of laparoscopic radiofrequency ablation of hepatocellular carcinoma in patients with liver cirrhosis.

Authors:  R Santambrogio; M Podda; M Zuin; E Bertolini; S Bruno; G P Cornalba; M Costa; M Montorsi
Journal:  Surg Endosc       Date:  2003-06-17       Impact factor: 4.584

Review 7.  Recent progress in cryoablation cancer therapy and nanoparticles mediated cryoablation.

Authors:  Kijung Kwak; Bo Yu; Robert J Lewandowski; Dong-Hyun Kim
Journal:  Theranostics       Date:  2022-02-14       Impact factor: 11.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.